	US 12,122,826 B2
	Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
Gregg Timony, Carlsbad, CA (US); Sheila Gujrathi, Rancho Santa Fe, CA (US); Robert Peach, San Diego, CA (US); and Allan Olson, San Diego, CA (US)
Assigned to AbbVie Inc.
Filed by AbbVie Inc., North Chicago, IL (US)
Filed on May 10, 2022, as Appl. No. 17/740,988.
Application 17/740,988 is a division of application No. 16/092,943, granted, now 11,390,669, previously published as PCT/US2017/029768, filed on Apr. 27, 2017.
Claims priority of provisional application 62/328,539, filed on Apr. 27, 2016.
Prior Publication US 2022/0281968 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 31/58 (2006.01); A61K 38/13 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 37/06 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/58 (2013.01); A61K 38/13 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 37/06 (2018.01); C07K 2317/56 (2013.01)]

27 Claims

1. A method of treating eosinophilic esophagitis (EoE) in a subject, comprising administering an anti-IL-13 antibody, or antigen binding fragment thereof, to the subject weekly, thereby treating EoE in the subject, wherein the anti-IL-13 antibody, or antigen-binding fragment thereof, comprises six CDRs:

CDR-H1-residues 31-37 of SEQ ID NO:2,

CDR-H2-residues 52-67 of SEQ ID NO:2,

CDR-H3-residues 100-112 of SEQ ID NO:2;

CDR-L1-residues 24-34 of SEQ ID NO:3,

CDR-L2-residues 50-56 of SEQ ID NO:3, and

CDR-L3-residues 89-97 of SEQ ID NO:3;

thereby reducing mean dysphagia symptom composite diary score in the subject by at least 5 points when compared to a subject not treated with the anti-IL-13 antibody, or antigen binding fragment thereof.